Clinical Trials Logo

Clinical Trial Summary

RATIONALE: Drugs, such as prednisone and dexamethasone, may change the immune system and be an effective treatment for primary immune thrombocytopenic purpura. It is not yet known which drug is more effective in treating primary immune thrombocytopenic purpura.

PURPOSE: This randomized phase III trial is studying high-dose dexamethasone to see how well it works compared to standard-dose prednisone in treating patients with newly diagnosed, previously untreated primary immune thrombocytopenic purpura.


Clinical Trial Description

OBJECTIVES:

Primary

- To evaluate the role of therapy intensification in adult patients with newly diagnosed, previously untreated primary immune thrombocytopenic purpura with high-dose dexamethasone (HD-DXM), in terms of improvement of response at 6 months after initial response, in comparison with standard-doses of prednisone.

Secondary

- Compare rate of initial response.

- Compare quality of response.

- Compare rate of final responses and rate of persistent response.

- Compare rate of bleeding events.

- Determine rate of resumed response with HD-DXM in non-responder patients or patients who have lost response (arm I only).

- Compare time to platelet number increase until a hemostatically effective level is reached and/or disappearance of bleeding symptoms.

- Compare rate of rescue interventions.

- Compare rate of eligible patients for splenectomy.

- Compare rate of patients who underwent splenectomy.

- Compare rate of patients who develop connective tissue diseases or underlying hematological diseases (myelodysplastic syndromes, chronic lymphoproliferative diseases, others).

- Compare patient's self reported quality of life.

OUTLINE: This is a multicenter study. Patients are stratified by treating center. Patients are randomized to 1 of 2 treatment arms.

- Arm I (Standard-dose prednisone): Patients receive oral prednisone at a standard dose (1 mg/Kg) once daily on days 1-28 followed by a 14-day taper.

Patients considered non-responders at day 42 or who have lost response before evaluation of final response (day 180) are crossed to arm II.

- Arm II (High-dose dexamethasone): Patients receive oral dexamethasone at a high dose (40 mg/day) once daily on days 1-4. Treatment repeats every 14 days for 3 courses.

Quality of life is assessed at baseline, on day 42 (arm I) or 46 (arm II) (initial response evaluation day), 180 days after initial response evaluation, and at 3, 9, 12 months after randomization.

After completion of study treatment, patients are followed monthly until 1 year after randomization, every 2 months for 1 year, and then every 3 months for 1 year. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00657410
Study type Interventional
Source Gruppo Italiano Malattie EMatologiche dell'Adulto
Contact
Status Completed
Phase Phase 3
Start date April 2008
Completion date February 2016

See also
  Status Clinical Trial Phase
Recruiting NCT00986557 - T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant Phase 2
Completed NCT00132015 - 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis Phase 2
Active, not recruiting NCT00334672 - Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis Phase 3
Completed NCT01147991 - Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer Phase 1
Completed NCT00955591 - Comparing Two Types of Swabs in Collecting Cell Samples for Anal Pap Tests and Human Papillomavirus Tests in Men Who Have Sex With Men N/A
Completed NCT01209325 - Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males Phase 2
Terminated NCT01319526 - Biomarkers in Blood Samples From Patients With HIV Infection and Stage III or Stage IV Hodgkin Lymphoma Undergoing Chemotherapy
Completed NCT00822120 - S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma Phase 2
Completed NCT00919997 - Human Papilloma Virus Infection in HIV-Positive Indian Men Who Have Sex With Men N/A
Completed NCT00381875 - Vaccine Therapy, Incomplete Freund's Adjuvant, and GM-CSF in Treating Patients With HIV Phase 1
Completed NCT00486421 - Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura Phase 0
Completed NCT00716911 - Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant N/A
Active, not recruiting NCT01490801 - Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma N/A
Completed NCT00722839 - Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants Phase 1
Completed NCT00981097 - Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
Completed NCT00667563 - Vaccine Therapy in Preventing HPV in HIV-Positive Women in India Phase 1
Completed NCT01164722 - Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia Phase 3